489 related articles for article (PubMed ID: 31196118)
21. Dose distribution and tumor control probability in out-of-field lymph node stations in intensity modulated radiotherapy (IMRT) vs 3D-conformal radiotherapy (3D-CRT) of non-small-cell lung cancer: an in silico analysis.
Fleckenstein J; Eschler A; Kremp K; Kremp S; Rübe C
Radiat Oncol; 2015 Aug; 10():178. PubMed ID: 26292716
[TBL] [Abstract][Full Text] [Related]
22. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma.
Lertbutsayanukul C; Prayongrat A; Kannarunimit D; Chakkabat C; Netsawang B; Kitpanit S
Strahlenther Onkol; 2018 May; 194(5):375-385. PubMed ID: 29302704
[TBL] [Abstract][Full Text] [Related]
23. Fully automated VMAT treatment planning for advanced-stage NSCLC patients.
Della Gala G; Dirkx MLP; Hoekstra N; Fransen D; Lanconelli N; van de Pol M; Heijmen BJM; Petit SF
Strahlenther Onkol; 2017 May; 193(5):402-409. PubMed ID: 28314877
[TBL] [Abstract][Full Text] [Related]
24. Dosimetric comparison of single-arc/partial-arc volumetric modulated arc therapy and intensity-modulated radiotherapy for peripheral and central lung cancer.
Akcay M; Etiz D; Duruer K; Bozdogan O; Ozen A
J Cancer Res Ther; 2021; 17(1):80-87. PubMed ID: 33723136
[TBL] [Abstract][Full Text] [Related]
25. Intensity-modulated radiotherapy and volumetric-modulated arc therapy have distinct clinical advantages in non-small cell lung cancer treatment.
Zhang J; Yu XL; Zheng GF; Zhao F
Med Oncol; 2015 Apr; 32(4):94. PubMed ID: 25725813
[TBL] [Abstract][Full Text] [Related]
26. Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer.
Zhou L; Liu J; Xue J; Xu Y; Gong Y; Deng L; Wang S; Zhong R; Ding Z; Lu Y
Radiat Oncol; 2014 May; 9():117. PubMed ID: 24884773
[TBL] [Abstract][Full Text] [Related]
27. Twice-daily thoracic radiotherapy by intensity-modulated radiation therapy (IMRT) compared with simultaneous integrated boost IMRT (SIB-IMRT) with concurrent chemotherapy for patients with limited-stage small cell lung cancer. A propensity-score matched analysis.
Sun H; Liu C; Zhang J; Yang G; Han D; Liu T; Huang W; Li B
Radiother Oncol; 2022 Jul; 172():140-146. PubMed ID: 35101460
[TBL] [Abstract][Full Text] [Related]
28. Salvage radiotherapy with simultaneous integrated boost in non small-cell lung cancer patients with mediastinal relapse after surgery: a pilot study.
Nicosia L; Agolli L; Reverberi C; De Sanctis V; Marinelli L; Minniti G; Di Muzio J; Valeriani M; Osti MF
Radiat Oncol; 2018 Oct; 13(1):207. PubMed ID: 30352607
[TBL] [Abstract][Full Text] [Related]
29. Hippocampal avoidance with volumetric modulated arc therapy in melanoma brain metastases - the first Australian experience.
Awad R; Fogarty G; Hong A; Kelly P; Ng D; Santos D; Haydu L
Radiat Oncol; 2013 Mar; 8():62. PubMed ID: 23497418
[TBL] [Abstract][Full Text] [Related]
30. IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: A direct comparison of PET-based treatment planning.
Fleckenstein J; Kremp K; Kremp S; Palm J; Rübe C
Strahlenther Onkol; 2016 Feb; 192(2):75-82. PubMed ID: 26438071
[TBL] [Abstract][Full Text] [Related]
31. Randomized controlled study comparing simultaneous modulated accelerated radiotherapy versus simultaneous integrated boost intensity modulated radiotherapy in the treatment of locally advanced head and neck cancer.
Tandon S; Gairola M; Ahlawat P; Rawat S; Aggarwal A; Sharma K; Tiwari S; Karimi AM; Muttagi V; Sachdeva N; Bhushan M
J Egypt Natl Canc Inst; 2018 Sep; 30(3):107-115. PubMed ID: 29960876
[TBL] [Abstract][Full Text] [Related]
32. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
Eze C; Taugner J; Roengvoraphoj O; Schmidt-Hegemann NS; Käsmann L; Wijaya C; Belka C; Manapov F
Radiat Oncol; 2019 Sep; 14(1):163. PubMed ID: 31484542
[TBL] [Abstract][Full Text] [Related]
33. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
[TBL] [Abstract][Full Text] [Related]
34. Voxel-Level BED Corrected Dosimetric and Radiobiological Assessment of 2 Kinds of Hybrid Radiotherapy Planning Methods for Stage III NSCLC.
Wang H; Huang Y; Chen H; Shao Y; Duan Y; Feng A; Gu H; Ma X; Xu Z; Kong Q; Zhou Y
Technol Cancer Res Treat; 2022; 21():15330338221107966. PubMed ID: 35731648
[No Abstract] [Full Text] [Related]
35. Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer.
Guckenberger M; Kavanagh A; Partridge M
Strahlenther Onkol; 2012 Oct; 188(10):894-900. PubMed ID: 22933031
[TBL] [Abstract][Full Text] [Related]
36. Critical dose and toxicity index of organs at risk in radiotherapy: analyzing the calculated effects of modified dose fractionation in non-small cell lung cancer.
Pedicini P; Strigari L; Benassi M; Caivano R; Fiorentino A; Nappi A; Salvatore M; Storto G
Med Dosim; 2014; 39(1):23-30. PubMed ID: 24239409
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
38. [Application value of reduced field intensity modulated radiation therapy for advanced cervical cancer].
DU XL; Sheng XG; Wang C; Yu H; Song QQ; Pan CX
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):925-31. PubMed ID: 24506963
[TBL] [Abstract][Full Text] [Related]
39.
Qiu J; Lv B; Fu M; Wang X; Zheng X; Zhuo W
Head Neck; 2017 Dec; 39(12):2519-2527. PubMed ID: 28963789
[TBL] [Abstract][Full Text] [Related]
40. Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer.
Zhang Q; Cai XW; Feng W; Yu W; Fu XL
BMC Cancer; 2022 Jan; 22(1):96. PubMed ID: 35065627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
